4//SEC Filing
Breen Michael Martin 4
Accession 0001654954-21-012057
CIK 0000109657other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 12:01 PM ET
Size
13.9 KB
Accession
0001654954-21-012057
Insider Transaction Report
Form 4
Breen Michael Martin
Director
Transactions
- Award
Common Stock
2021-02-16+278,058→ 278,058 total - Conversion
Common Stock
2021-02-25$3.40/sh+9,859$33,521→ 328,160 total - Conversion
10% Senior Convertible Debenture
2021-02-25−30,000→ 0 totalExercise: $3.40From: 2020-06-23Exp: 2021-06-23→ Common Stock (9,859 underlying) - Conversion
Common Stock
2021-02-25$3.40/sh+40,243$136,826→ 318,301 total - Award
Option to purchase Common Stock
2021-02-16+50,000→ 50,000 totalExercise: $6.33Exp: 2031-02-15→ Common Stock (50,000 underlying) - Conversion
10% Senior Convertible Debenture
2021-02-25−100,000→ 0 totalExercise: $3.40From: 2018-09-07→ Common Stock (40,243 underlying)
Footnotes (3)
- [F1]Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on January 13, 2021, 2022 and 2023.
- [F2]1/3rd of the shares vest on February 16, 2021, 2022 and 2023.
- [F3]While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding until converted.
Documents
Issuer
GT Biopharma, Inc.
CIK 0000109657
Entity typeother
Related Parties
1- filerCIK 0001863633
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 12:01 PM ET
- Size
- 13.9 KB